Unlike LCAT however, LPLA2 does not require apoA-I activation, and is only active in an acidic environment, rendering it susceptible to inhibition by a variety of other commonly used cationic amphipathic drugs that interfere with lysosomal acidification and cause phospholipidosis in otherwise normal subjects [30]. The gene discussed is LCAT; the disease is lysosomal storage disease.